<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Antimicrobial Agents and Chemotherapy"><meta name="citation_title" content="Bactericidal and Morphological Effects of NE-2001, a Novel Synthetic Agent Directed against Helicobacter pylori"><meta name="citation_authors" content="Guofei Dai, Ni Cheng, Lei Dong, Mutsumi Muramatsu, Shudong Xiao, Ming-Wei Wang, and  De-Xu Zhu"><meta name="citation_date" content="2005 August"><meta name="citation_issue" content="8"><meta name="citation_volume" content="49"><meta name="citation_firstpage" content="3468"><meta name="citation_doi" content="10.1128/AAC.49.8.3468-3473.2005"><meta name="citation_pdf_url" content="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1196265&amp;blobtype=pdf"><meta name="citation_abstract_html_url" content="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1196265&amp;rendertype=abstract"><meta name="citation_fulltext_html_url" content="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1196265"><meta name="citation_pmid" content="16048962"><meta name="DC.Title" content="Bactericidal and Morphological Effects of NE-2001, a Novel Synthetic Agent Directed against Helicobacter pylori"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="American Society for Microbiology (ASM)"><meta name="DC.Contributor" content="Guofei Dai"><meta name="DC.Contributor" content="Ni Cheng"><meta name="DC.Contributor" content="Lei Dong"><meta name="DC.Contributor" content="Mutsumi Muramatsu"><meta name="DC.Contributor" content="Shudong Xiao"><meta name="DC.Contributor" content="Ming-Wei Wang"><meta name="DC.Contributor" content="De-Xu Zhu"><meta name="DC.Date" content="2005 August"><meta name="DC.Identifier" content="10.1128/AAC.49.8.3468-3473.2005"><meta name="DC.Language" content="en"><link rel="stylesheet" href="corehtml/pmc/css/pmcstatic.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcbase1.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcbars-slateblue.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcbody9.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcrefs4.css" type="text/css"><script type="text/javascript" src="corehtml/pmc/js/common.js"></script><script type="text/javascript">window.name="mainwindow";</script><link href="http://www.ncbi.nlm.nih.gov/corehtml/jsutils/css/tileshop_pmc.1/tileshop_pmc.1.css" type="text/css" rel="stylesheet"><script type="text/javascript" src="http://www.ncbi.nlm.nih.gov/corehtml/jsutils/utils.1.js"></script><script>utils.jsLoader.sBase = "http://www.ncbi.nlm.nih.gov/corehtml/jsutils/";</script><script type="text/javascript" src="http://www.ncbi.nlm.nih.gov/corehtml/jsutils/tileshop_pmc.1/tileshop_pmc.1.js"></script><script type="text/javascript" src="http://www.ncbi.nlm.nih.gov/corecgi/tileshop/tileshop_data_db.1.js"></script><title>Bactericidal and Morphological Effects of NE-2001, a Novel Synthetic Agent Directed against Helicobacter pylori</title></head><body class="pmc-body"><a id="top" name="top"></a><table cellpadding="0" cellspacing="0" width="100%" border="0"><tr valign="top"><td colspan="3"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse;"><tr><td width="145" valign="top"><img src="corehtml/pmc/pmcgifs/pmc3_logo_v5.gif" border="0" usemap="#pmclogo" alt="pmc logo image"><map name="pmclogo"><area shape="rect" alt="Journal List" coords="65,52,137,67" href="fprender.fcgi"><area shape="rect" alt="Search" coords="7,52,52,67" href="redirect3.cgi?&amp;&amp;auth=0Byhc0xk1_3EhdWeHIn7FkSXDpQtxvcN6KQtHmAUP&amp;reftype=other&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CLogo&amp;TO=Entrez%7CSearch%7CAll%20PMC&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc"><area shape="rect" alt="pmc logo image" coords="0,0,145,75" href="./"></map></td><td height="75" valign="top" style="padding-left: 4px;"><div><img align="top" border="0" src="corehtml/pmc/pmcgifs/logo-aac.gif" alt="Logo of aac" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" alt="Antimicrob Agents Chemother Subscriptions" coords="0,64,190,75" href="redirect3.cgi?&amp;&amp;auth=06ELuGNpiKkohsM7Jt7p0JXgw-UdEzxKJYsXY3Q2k&amp;reftype=publisher&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://aac.asm.org/subscriptions/" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="DEFAULT" alt="Antimicrob Agents Chemother Web Site" coords="0,0,500,75" href="redirect3.cgi?&amp;&amp;auth=0rkDG9hSszQ9pW0MHw4jhuxh3CHdbP7xR6aprvQtD&amp;reftype=publisher&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://aac.asm.org" target="pmc_ext" onclick="focuswin('pmc_ext')"></map></div></td></tr></table></td></tr></table><table cellpadding="0" cellspacing="3" width="100%" border="0"><tr><td></td><td colspan="2"><div class="navlink-box navlink-box-gray"><a href="fprender.fcgi" class="navlink">Journal List</a><span> &gt; </span><a class="navlink" href="tocrender.fcgi?journal=82&amp;action=archive">Antimicrob Agents Chemother</a><span> &gt; </span><a class="navlink" href="tocrender.fcgi?iid=120965">v.49(8); Aug 2005</a></div></td></tr><tr><td width="145" valign="top" class="sidebar-cell"><div class="sidebar-article-navigation-box"><div class="sidefm-pmclink-item"><a href="articlerender.fcgi?artid=1196265&amp;rendertype=abstract" class="sidefm-pmclink">Abstract</a></div><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Full Text</a></div><div class="sidefm-pmclink-item"><a href="picrender.fcgi?artid=1196265&amp;blobtype=pdf" class="sidefm-pmclink">PDF (215K)</a></div><div class="sidefm-pmclink-item"><a href="tocrender.fcgi?iid=120965" class="sidefm-pmclink">Contents</a></div><div class="sidefm-pmclink-item"><a href="tocrender.fcgi?journal=82&amp;action=archive" class="sidefm-pmclink">Archive</a></div><div class="sidefm-pmclink-item"><a href="tocrender.fcgi?journal=82&amp;action=homepage" class="sidefm-pmclink">Journal Homepage</a></div></div><div class="sidebar-pubmed-box"><div class="sidebar-pubmed-links-to-box"><form name="pubmedLinks" onsubmit="return pubMedDbLinkSubmit(this)"><div class="sidefm-pmsubhead"><label for="pubmedOption">Related material:</label></div><select name="pubmedOption" id="pubmedOption" class="sidefm-pmart" onchange="return pubMedDbLinkSubmit(this)"><option value="redirect3.cgi?&amp;&amp;auth=0zU7c4Y1IQU6KQog_aToEhwzRQpDBX5ywCIIY6kdU&amp;reftype=abs&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article|Navigation&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/16048962">PubMed record</option><option selected value="redirect3.cgi?&amp;&amp;auth=0Te5rUYAiRgynyli2DO2-u7nDnvGj0CiGFodYCkJG&amp;reftype=relart&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article|Navigation&amp;TO=Entrez|PubMed|Related%20Records&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Link&amp;dbFrom=PubMed&amp;from_uid=16048962">PubMed related arts</option><option value="redirect3.cgi?&amp;&amp;auth=0fgTimTMqWJQozHRqaPdbX0162X5GW21BxTr8hA_s&amp;reftype=linkout&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article|Navigation&amp;TO=Entrez|PubMed|Linkout&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowLinkOut&amp;TermToSearch=16048962">PubMed LinkOut</option><option value="redirect3.cgi?&amp;&amp;auth=049m7hU_WPH5C5BsVzCBQx-LWo3bmi9NSQ_qyF5v3&amp;reftype=Compound&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc&amp;cmd=Display&amp;from_uid=1196265&amp;dopt=pmc_pccompound">Compound</option><option value="redirect3.cgi?&amp;&amp;auth=04YSqo6lbhnSrlx6Yff7uXvok9XSxRzwbKawlb5QE&amp;reftype=Substance&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc&amp;cmd=Display&amp;from_uid=1196265&amp;dopt=pmc_pcsubstance">Substance</option><option value="redirect3.cgi?&amp;&amp;auth=0TwgbS2SglEYHteIAJ1sURLfB7wjaRGUFvpt_Yk37&amp;reftype=Taxonomy&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc&amp;cmd=Display&amp;from_uid=1196265&amp;dopt=pmc_taxonomy">Taxonomy</option><option value="redirect3.cgi?&amp;&amp;auth=0nuGOQzcEprMA4O93OP22_CURGP3GFtBr7yFctQ2_&amp;reftype=Taxonomy&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?Db=taxonomy&amp;DbFrom=pmc&amp;cmd=Link&amp;LinkName=pmc_taxonomy&amp;doptcmdl=TxTree&amp;IdsFromResult=1196265">Taxonomy tree</option></select><br><input type="image" src="corehtml/pmc/pmcgifs/go.gif" alt="Go" class="sidefm-pmart"></form></div><div class="sidebar-pubmed-author-box"><div class="sidefm-pmsubhead">PubMed articles by:</div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=0P_12tTFAzQSwjO4AJ0xBcod-Zz5T16k7LySBJ5LX&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Dai+G%5Bauth%5D" class="sidefm-pmclink"> Dai, G.</a></div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=0Leth1l11mrwUBlCiNzfrJwZRdUtRvZHAzrDOgQZq&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Cheng+N%5Bauth%5D" class="sidefm-pmclink"> Cheng, N.</a></div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=0073Og8qHTyMC9_Fgaz2VOGp3jwUUwZX0A83IqAcl&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Dong+L%5Bauth%5D" class="sidefm-pmclink"> Dong, L.</a></div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=0POh_ABIapKkvtF4VeFrUKEHJ-fo5r3YqWxKHUkYR&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Zhu+DX%5Bauth%5D" class="sidefm-pmclink"> Zhu, D.</a></div></div></div></td><td rowspan="103" width="20px" height="300" background="corehtml/pmc/pmcgifs/wm-aac.gif"><div style="width:20px"></div></td><td valign="top" class="content-cell"><div class="front-matter-section"><table cellspacing="0" cellpadding="0" width="100%"><tr style="vertical-align: top"><td><div class="fm-citation"><div><span class="citation-abbreviation">Antimicrob Agents Chemother. </span><span class="citation-publication-date">2005 August; </span><span class="citation-volume">49</span><span class="citation-issue">(8)</span><span class="citation-flpages">: 3468–3473. </span></div><div><span class="fm-vol-iss-date"> </span><span class="fm-vol-iss-date">doi: 10.1128/AAC.49.8.3468-3473.2005.</span></div></div></td><td class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span>PMC1196265</div></td></tr></table><div class="fm-copyright"><a class="int-reflink" href="about/copyright.html">Copyright</a>  &#x000a9; 2005, American Society for Microbiology</div><div class="fm-title">Bactericidal and Morphological Effects of NE-2001, a Novel Synthetic Agent Directed against <em>Helicobacter pylori</em></div><div class="fm-author contrib-group">Guofei Dai,<sup>2</sup><sup>&#x02020;</sup> Ni Cheng,<sup>1</sup><sup>&#x02020;</sup> Lei Dong,<sup>1</sup> Mutsumi Muramatsu,<sup>1</sup> Shudong Xiao,<sup>3</sup> Ming-Wei Wang,<sup>2,</sup><sup>4</sup><sup>&#x0002a;</sup> and  De-Xu Zhu<sup>1</sup><sup>&#x0002a;</sup><div class="fm-affl">State Key Laboratory of Pharmaceutical Biotechnology, Department of Biochemistry, Nanjing University, Nanjing 210093, People's Republic of China,<sup>1</sup> The National Center for Drug Screening, Shanghai Institute of Materia Medica and Graduate School, Chinese Academy of Sciences, Shanghai 201203, People's Republic of China,<sup>2</sup> Laboratory of Gastroenterology, Ministry of Public Health, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, People's Republic of China,<sup>3</sup> Shanghai East Best Biopharmaceutical Enterprises Co., Ltd., Shanghai 200233, People's Republic of China<sup>4</sup></div></div><div class="fm-footnote"></div><div class="fm-footnote" id="cor1"><sup>&#x0002a;</sup>Corresponding author. Mailing address for De-Xu Zhu: Department of Biochemistry, Nanjing University, Nanjing 210093, P.R. China. Phone: 86 25 8359 2405. Fax: 86 25 83324605. E-mail: <span class="e_id106952">zjq/at/nju.edu.cn</span><script type="text/javascript" language="JavaScript"><!--
                                    try{initUnObscureEmail ("e_id106952", '<a class="ext-reflink" href="' + reverseAndReplaceString('nc.ude.ujn/ta/qjz:otliam', '/at/', '@') + '">' + reverseAndReplaceString('nc.ude.ujn/ta/qjz', '/at/','@') + '</a>')}catch(e){}
                                //--></script>. Mailing address for Ming-Wei Wang: The National Center for Drug Screening, Shanghai 201203, P.R. China. Phone: 86 21 5080 0598. Fax: 86 21 5080 0721. E-mail: <span class="e_id106957">center/at/mail.shcnc.ac.cn</span><script type="text/javascript" language="JavaScript"><!--
                                    try{initUnObscureEmail ("e_id106957", '<a class="ext-reflink" href="' + reverseAndReplaceString('nc.ca.cnchs.liam/ta/retnec:otliam', '/at/', '@') + '">' + reverseAndReplaceString('nc.ca.cnchs.liam/ta/retnec', '/at/','@') + '</a>')}catch(e){}
                                //--></script>.</div><div class="fm-footnote" id="fn1"><sup>&#x02020;</sup>G.D. and N.C. contributed equally to the work.</div><div class="fm-pubdate">Received July 3, 2004; Revised September 5, 2004; Accepted May 5, 2005.</div><div class="links-box"><div class="fm-footnote"><img src="corehtml/pmc/pmcgifs/rt-arrow.gif" alt="Small right arrow pointing to:" style="vertical-align: middle;"> This article has been <a class="int-reflink" href="tocrender.fcgi?artid=1196265&amp;action=cited">cited by</a> other articles in PMC.</div></div></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: uppercase;">Top</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: uppercase;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Abstract</a></div><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323446" class="sidefm-pmclink" style="text-transform: uppercase;">MATERIALS AND METHODS</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323680" class="sidefm-pmclink" style="text-transform: uppercase;">RESULTS</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323998" class="sidefm-pmclink" style="text-transform: uppercase;">DISCUSSION</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id324266" class="sidefm-pmclink" style="text-transform: uppercase;">REFERENCES</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: uppercase;" id="id323173">Abstract</div><div class="section-content"><!--article-meta-->The antibacterial activities of NE-2001 were tested against 24 clinical isolates of <em>Helicobacter pylori</em> and compared with those of amoxicillin, clarithromycin, metronidazole, and furazolidone. The MIC<sub>50</sub> and MIC<sub>90</sub> of this synthetic compound on the isolates were 8 and 16 &#x003bc;g/ml, respectively. This action was highly selective against <em>Helicobacter pylori</em>; there was a &#x0003e;4-fold difference between the concentration of NE-2001 required to inhibit the growth of <em>Helicobacter pylori</em> and that required to inhibit the growth of common aerobic and anaerobic bacteria. Exposure of <em>Helicobacter pylori</em> (ATCC43504) to NE-2001 at the MIC (4 &#x003bc;g/ml), or at a greater concentration, resulted in an extensive loss of viability. The phenomenon was also observed at pH levels between 3.0 and 7.0. When two clinical <em>Helicobacter pylori</em> strains were successively cultured at subinhibitory concentrations of NE-2001, no significant changes in the bactericidal effects were found. The morphological alterations of <em>Helicobacter pylori</em> cells (ATCC43504), exposed to NE-2001 at various concentrations for 6 h, were observed using transmission electron microcopy. The bacterium displayed features such as swelling, vacuole-like structures in the cytoplasm, and cell destruction following exposure to NE-2001. The efficacy of NE-2001 was maintained when evaluated in eight clinical isolates resistant to metronidazole and five isolates resistant to both metronidazole and clarithromycin (MIC ranging between 4 and 16 &#x003bc;g/ml). The above-described results suggest that NE-2001 may have the potential to be developed as a candidate agent for the treatment of <em>Helicobacter pylori</em> infection.</div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: uppercase;">Top</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323173" class="sidefm-pmclink" style="text-transform: uppercase;">Abstract</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323446" class="sidefm-pmclink" style="text-transform: uppercase;">MATERIALS AND METHODS</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323680" class="sidefm-pmclink" style="text-transform: uppercase;">RESULTS</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323998" class="sidefm-pmclink" style="text-transform: uppercase;">DISCUSSION</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id324266" class="sidefm-pmclink" style="text-transform: uppercase;">REFERENCES</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: uppercase;" id="id323233"> </div><div class="section-content"><em>Helicobacter pylori</em> (<em>H. pylori</em>) is a ubiquitous gram-negative, microaerophilic spiral bacterium infecting half the world's population and causing chronic active gastritis in virtually all infected individuals (<a href="#r5" class="cite-reflink bibr">5</a>). The majority of patients who acquire chronic <em>H. pylori</em> infection exhibit mild gastritis (<a href="#r7" class="cite-reflink bibr">7</a>). Epidemiological, laboratory, and interventional human studies strongly suggest that <em>H. pylori</em> plays a pathogenic role in the development of adenocarcinoma of the distal stomach (<a href="#r6" class="cite-reflink bibr">6</a>). The mechanisms by which <em>H. pylori</em> may cause gastroduodenal disease and contribute to gastric carcinogenesis are still hypothetical. However, the production of specific virulence factors by the bacterium, the inflammatory response of the host, and the association with environmental contributors may all be responsible (<a href="#r3" class="cite-reflink bibr">3</a>).<p>Treatment regimens for <em>H. pylori</em> infection have been evolving since the early 1990s, when monotherapy was first recommended. Antimicrobial therapy for this infection is a complex issue, and the following drugs are currently used in combination regimens: proton-pump inhibitors and/or bismuth, metronidazole, clarithromycin, and amoxicillin (<a href="#r14" class="cite-reflink bibr">14</a>). Tetracycline is used in the rescue therapy (<a href="#r8" class="cite-reflink bibr">8</a>). Although optimal first-line treatment is associated with high cure rates, the rising prevalence of resistance to the antibiotic component of current eradication regimens increasingly threatens to compromise the efficacy of these regimens. Strains resistant to metronidazole (<a href="#r9" class="cite-reflink bibr">9</a>) and clarithromycin (<a href="#r18" class="cite-reflink bibr">18</a>) have been well documented, while resistance to amoxicillin (<a href="#r23" class="cite-reflink bibr">23</a>) and tetracycline was mainly reported in Asia (<a href="#r11" class="cite-reflink bibr">11</a>). Therapeutic regimens directed against <em>H. pylori</em> infection will continue to evolve. What is required is a simpler and more efficacious strategy for the treatment of <em>H. pylori</em> infection. New antibiotics with the following characteristics have been sought among many synthetic compounds and secondary metabolites of microorganisms: (i) high specificity for <em>H. pylori</em>; (ii) stability in 0.1 N HCl; and (iii) lower frequency of natural resistance. Following vigorous screening of various compound libraries, NE-2001, a small synthetic molecule with the novel structure 4-(4-methylbenzyl)-4&#x02032;-[guanidinomethylbenzoyloxy]biphenyl-4-carboxylate hydrochloride (Fig. <a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">1</a>), was discovered to demonstrate a specific inhibitory effect on the growth of <em>H. pylori</em> in vitro (<a href="#r24" class="cite-reflink bibr">24</a>). It was proposed that the mechanism of action by which NE-2001 exerts its anti-<em>H. pylori</em> activity may relate to suppression of bacterial DNA synthesis (<a href="#r4" class="cite-reflink bibr">4</a>). In the present study, we investigated the effects of NE-2001 on the viability, urease activity, and morphology of <em>H. pylori</em> in vitro, in conjunction with resistance development following repeated exposure and its ability to inhibit the growth of metronidazole- and clarithromycin-resistant strains of the bacterium.</p><div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="f1" name="f1"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f1" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=1196265&amp;blobname=zac0080551270001.gif" border="1" class="icon-reflink" alt="FIG. 1." title="FIG. 1."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f1" onclick="startTarget(this, 'figure', 1024, 800)"><strong>FIG. 1.</strong></a><div class="figure-table-caption-in-article"><span>Chemical structure of NE-2001.</span></div></td></tr></table></div></div><div style="clear:both;"></div></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: uppercase;">Top</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323173" class="sidefm-pmclink" style="text-transform: uppercase;">Abstract</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: uppercase;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>MATERIALS AND METHODS</a></div><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323680" class="sidefm-pmclink" style="text-transform: uppercase;">RESULTS</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323998" class="sidefm-pmclink" style="text-transform: uppercase;">DISCUSSION</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id324266" class="sidefm-pmclink" style="text-transform: uppercase;">REFERENCES</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: uppercase;" id="id323446">MATERIALS AND METHODS</div><div class="section-content"><p><span class="head2">Bacterial strains. </span> Clinical isolates of <em>H. pylori</em> were randomly collected from 50 patients (aged between 30 and 61 years), consulted at Renji Hospital in Shanghai and Jiangsu People's Hospital in Nanjing, China, who suffered from duodenal ulcer, reflux esophagitis, chronic superficial gastritis, chronic atrophic gastritis, and chronic erosive gastritis diagnosed by endoscopy and/or histology. Gastric biopsy specimens were collected from antrum of the stomach, before or after first-line treatment, and identified for <em>H. pylori</em> infection according to morphology by Gram staining and oxidase, catalase, and urease reactions (<a href="#r19" class="cite-reflink bibr">19</a>). These isolates were maintained frozen at &#x02212;70&#x000b0;C before experimentation. The standard strain ATCC43504 was used for experimental and quality control purposes. The laboratory standard strains of common aerobic and anaerobic bacteria were obtained from our culture collection.</p><p><span class="head2">Antibacterial agents. </span> NE-2001 was prepared using the method described previously (<a href="#r24" class="cite-reflink bibr">24</a>). Amoxicillin, metronidazole, and furazolidone were commercially available (Sigma Chemical Co., St. Louis, MO). Clarithromycin was obtained from Livzon Pharmaceutical Group Inc. (Zhuhai, Guangdong, China). Amoxicillin and furazolidone were dissolved in dimethyl sulfoxide (DMSO), metronidazole in water, and clarithromycin in acetone. NE-2001 was dissolved in a 2-hydroxypropyl-&#x003b2;-cyclodextrin (Sigma) solution (molar ratio &#x0003d; 1:10; prepared at 50&#x000b0;C for 30 min). These stock solutions were serially diluted in sterile water to give final concentrations on the day of use.</p><p><span class="head2">Susceptibility testing. </span> The MICs for <em>H. pylori</em> were determined by an agar dilution method (<a href="#r16" class="cite-reflink bibr">16</a>) with minor modification. Briefly, Mueller-Hinton agar (Oxoid, Basingstoke, U.K.) plates (10 ml/each) were prepared containing 7% lysed horse blood (Shanghai Institute of Biological Products, China) and twofold serial dilutions of the test compounds. They were inoculated with 5 &#x003bc;l of each bacterial suspension (10<sup>7</sup> CFU/ml) by use of a multipoint inoculator (Sakuma, Tokyo, Japan) and incubated at 37&#x000b0;C for 3 days in an incubator in a microaerobic atmosphere consisting of 5% O<sub>2</sub>, 10% CO<sub>2</sub>, and 85% N<sub>2</sub> with 98% humidity (Napco Co., Winchester, VA). An antibiotics-free plate and plates with corresponding dilutions of DMSO or 2-hydroxypropyl-&#x003b2;-cyclodextrin were used as negative controls to ensure bacteria viability and no contaminants in the inoculums. The MICs for other common bacteria were also determined by the agar dilution method using Mueller-Hinton agar inoculated with respective bacteria suspensions.</p><p><span class="head2">Bactericidal activity. </span> Portions of Brucella broth with 10% fetal bovine serum (FBS) (10 ml) and 0.1% &#x003b2;-cyclodextrin (Sigma) containing various concentrations of NE-2001 were inoculated with the bacteria from an overnight culture to yield an initial cell concentration of approximately 10<sup>6</sup> CFU/ml. The cultures were shaken at 37&#x000b0;C in a microaerobic atmosphere, and 100 &#x003bc;l were removed at various time points (0, 3,6, 24, and 48 h). Viable bacteria were counted following 10-fold serial dilutions in Brucella broth with 10% FBS, and each strain was inoculated in triplicate onto Columbia agar (Difco Co., Sparks, MD) supplemented with 8% defibrinated sheep blood. Colonies were counted after 3 days of incubation in a microaerobic atmosphere. Bactericidal activities of NE-2001 under various pH conditions were also measured by altering the medium pH levels.</p><p><span class="head2">Assay for resistance development. </span> Two clinical isolates of <em>H. pylori</em>, adjusted to a cell density of approximately 10<sup>6</sup> CFU/ml in Brucella broth supplemented with 10% FBS, were exposed to serial twofold dilutions of NE-2001 and metronidazole, respectively. Following incubation at 37&#x000b0;C for 24 h, the MICs were recorded. The culture that attained turbidity comparable to that of the untreated culture in the presence of the highest level of the test agents was further exposed to increasing concentrations of NE-2001 or metronidazole. These procedures were repeated for up to 10 cycles, and fluctuations in MICs during the course of continued exposure were determined.</p><p><span class="head2">Urease activity measurement. </span> Three types of urease were used. Crude urease from <em>H. pylori</em> (ATCC43504) was prepared from the whole cell according to the method described by Dunn and colleagues (<a href="#r5" class="cite-reflink bibr">5</a>) with modifications. Briefly, bacterial cells, cultured overnight in Brucella broth supplemented with 10% FBS, were collected and suspended to reach a concentration of 10<sup>7</sup> cells/ml. The cell suspension was vortex mixed for 10 min and centrifuged at 1,500 &#x000d7; <em>g</em> for 15 min at 4&#x000b0;C to extract urease. The supernatant was frozen and stored at &#x02212;80&#x000b0;C until use. The stock solution was diluted with purified water after thawing, and 25-&#x003bc;l volumes containing 0.5 to 1.0 &#x003bc;g of protein were incubated with different concentrations of the test compounds for 60 min at 37&#x000b0;C. This was followed by the addition of 100 &#x003bc;l phosphate-buffered saline (PBS) buffer (pH 6.8) containing 500 mM urea, 0.02% phenol red, and 0.1 mM dithiothreitol in each sample. The ureases from <em>Bacillus pasteurii</em> and jack beans were purchased from Sigma and used as controls. Color development was monitored at 560 nm (25&#x000b0;C) during the 60-min incubation period.</p><p><span class="head2">Transmission electron microscopy. </span> <em>H. pylori</em> cells, after exposure to NE-2001 at 0, 2, 4, and 8 &#x003bc;g/ml for 6 h at 37&#x000b0;C under microaerobic conditions, were collected by centrifugation and treated with Karnovsky's fixative at 4&#x000b0;C for 24 h. The samples were then rinsed with 0.1 M PBS and stained with 1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4) at room temperature for 2 h. Following a wash with 0.1 M PBS, they were dehydrated for multiple times (15 min each) in escalating concentrations of ethanol (70%, 80%, 90%, 95%, and 100% [vol/vol]) and embedded in a Quetol mixture. Sections were cut with a diamond knife on a Porter-Blum MT6000 ultra microtone (RMC, Tucson, AZ) and stained with both 1% uranyl acetate and lead citrate. The sections were examined with a transmission electron microscope (Hitachi H-600; Hitachi, Tokyo, Japan) at an accelerating voltage of 75 kV.</p><p><span class="head2">Reversal of drug resistance by NE-2001. </span> A total of 27 of the above-described clinical isolates (including two from the same patient) were cultured on Columbia agar (Difco) supplemented with 7% lysed horse blood and then submitted to metronidazole and clarithromycin susceptibility testing, respectively, using the above-described agar dilution method. Eight strains resistant to metronidazole (breakpoint MIC, &#x0003e;8 &#x003bc;g/ml) (<a href="#r23" class="cite-reflink bibr">23</a>) and five strains resistant to both metronidazole and clarithromycin (breakpoint MIC, &#x0003e;2 &#x003bc;g/ml) (<a href="#r21" class="cite-reflink bibr">21</a>) were identified thereafter (from 12 patients). They were subcultured once to ascertain reliable growth before measurement of MICs for NE-2001.</p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: uppercase;">Top</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323173" class="sidefm-pmclink" style="text-transform: uppercase;">Abstract</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323446" class="sidefm-pmclink" style="text-transform: uppercase;">MATERIALS AND METHODS</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: uppercase;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>RESULTS</a></div><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323998" class="sidefm-pmclink" style="text-transform: uppercase;">DISCUSSION</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id324266" class="sidefm-pmclink" style="text-transform: uppercase;">REFERENCES</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: uppercase;" id="id323680">RESULTS</div><div class="section-content"><p><span class="head2">Antibacterial activity. </span> The ranges of MICs for NE-2001, amoxicillin, clarithromycin, metronidazole, and furazolidone against 24 clinical isolates of <em>H. pylori</em> and the minimal concentrations required to inhibit the growth of 50% (MIC<sub>50</sub>) and 90% (MIC<sub>90</sub>) of the isolates are shown in Table <a href="articlerender.fcgi?artid=1196265&amp;rendertype=table&amp;id=t1" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">1</a>. NE-2001 inhibited the growth of all the <em>H. pylori</em> strains tested, with MICs ranging between 4 and 16 &#x003bc;g/ml. No strain resistant to NE-2001 was found among the 24 clinical isolates. Both NE-2001 and metronidazole were shown to be inactive (MICs &#x0003e; 64 &#x003bc;g/ml) against a collection of four gram-positive (<em>Staphylococcus aureus</em> 209P JC, <em>Staphylococcus epidermidis</em> ATCC12228, <em>Enterococcus faecalis</em> ATCC29212, and <em>Bacillus subtilis</em> ATCC6633) and five gram-negative (<em>Escherichia coli</em> K12, <em>Providencia rettgeri</em> NIH96, <em>Pseudomonas aeruginosa</em> PAO-1, <em>Klebsiella pneumoniae</em> NCTC9632, and <em>Morganella morganii</em> KONO) bacteria compared to the results seen with amoxicillin or clarithromycin. Amoxicillin was unable to inhibit <em>Pseudomonas aeruginosa</em> PAO-1 and <em>Morganella morganii</em> KONO (MICs &#x0003e; 100 &#x003bc;g/ml), while clarithromycin had no effect on the growth of <em>Providencia rettgeri</em> NIH96, <em>Pseudomonas aeruginosa</em> PAO-1, and <em>Morganella morganii</em> KONO (MICs &#x0003e; 100 &#x003bc;g/ml).<div style="margin: 1em; margin-right: 2em;                                 border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="t1" name="t1"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1196265&amp;rendertype=table&amp;id=t1" class="icon-reflink" onclick="startTarget(this, 'table', 1024, 800)"><img src="corehtml/pmc/pmcgifs/table-icon.gif" border="1" class="icon-reflink" alt="TABLE 1." title="TABLE 1."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1196265&amp;rendertype=table&amp;id=t1" onclick="startTarget(this, 'figure', 1024, 800)"><strong>TABLE 1.</strong></a><div class="figure-table-caption-in-article"><span>Antibacterial activities of NE-2001, amoxicillin, clarithromycin, metronidazole, and furazolidone against 24 clinical isolates of <em>H. pylori</em></span></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head2">Bactericidal activity. </span> The killing kinetics of NE-2001 for <em>H. pylori</em> (ATCC43504) is summarized in Fig. <a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">2</a>. NE-2001 displayed a concentration-dependent bactericidal activity against <em>H. pylori</em>, and the number of viable organisms decreased progressively following exposure to 3.2 &#x003bc;g/ml or greater concentrations.<div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="f2" name="f2"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f2" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=1196265&amp;blobname=zac0080551270002.gif" border="1" class="icon-reflink" alt="FIG. 2." title="FIG. 2."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f2" onclick="startTarget(this, 'figure', 1024, 800)"><strong>FIG. 2.</strong></a><div class="figure-table-caption-in-article"><span>Bactericidal effects of NE-2001 on <em>H. pylori</em> ATCC43504 (MIC &#x0003d; 4 &#x003bc;g/ml). NE-2001 concentrations used were 0 (&#x02022;), 0.8 &#x003bc;g/ml (<img src="corehtml/pmc/pmcents/x25AA.gif" border="0" alt="[filled square]" />), 1.6 &#x003bc;g/ml (<img src="corehtml/pmc/pmcents/utrif.gif" border="0" alt="[filled triangle]" />), 3.2 &#x003bc;g/ml (<img src="corehtml/pmc/pmcents/cir.gif" border="0" alt="[open circle]" />), 6.4 &#x003bc;g/ml (&#x025a1;),</span><a class="side-caption" style="font-size: 100%;" href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f2" onclick="startTarget(this, 'figure', 1024, 800)"> (more ...)</a></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head2">Effect of NE-2001 on the viability of <em>H. pylori</em> at various pH levels. </span> As shown in Fig. <a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f3" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">3</a>, following exposure to NE-2001 at pH levels between 3.0 and 7.0, <em>H. pylori</em> (ATCC43504) lost its viability. NE-2001 displayed concentration-dependent bactericidal effects at all pH values tested. In particular, no cell growth was observed at 6 h after exposure to 12.8 &#x003bc;g/ml at pH 3.0.<div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="f3" name="f3"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f3" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=1196265&amp;blobname=zac0080551270003.gif" border="1" class="icon-reflink" alt="FIG. 3." title="FIG. 3."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f3" onclick="startTarget(this, 'figure', 1024, 800)"><strong>FIG. 3.</strong></a><div class="figure-table-caption-in-article"><span>Bactericidal effects of NE-2001 on <em>H. pylori</em> ATCC43504 (MIC &#x0003d; 4 &#x003bc;g/ml) at pH 7 (A), 6 (B), 5 (C), and 3 plus 10 mM urea (D). NE-2001 concentrations used were 0 (&#x02022;), 0.8 &#x003bc;g/ml (<img src="corehtml/pmc/pmcents/x25AA.gif" border="0" alt="[filled square]" />), 1.6 &#x003bc;g/ml (<img src="corehtml/pmc/pmcents/utrif.gif" border="0" alt="[filled triangle]" />),</span><a class="side-caption" style="font-size: 100%;" href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f3" onclick="startTarget(this, 'figure', 1024, 800)"> (more ...)</a></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head2">Effect of NE-2001 on resistance development. </span> There was no significant alteration in the susceptibilities of the <em>H. pylori</em> strains tested to NE-2001 following repeated exposure. Metronidazole, on the other hand, induced a rapid emergence of drug resistance (Fig. <a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f4" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">4</a>).<div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="f4" name="f4"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f4" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=1196265&amp;blobname=zac0080551270004.gif" border="1" class="icon-reflink" alt="FIG. 4." title="FIG. 4."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f4" onclick="startTarget(this, 'figure', 1024, 800)"><strong>FIG. 4.</strong></a><div class="figure-table-caption-in-article"><span>Development of resistance to NE-2001(&#x02022;) and metronidazole (<img src="corehtml/pmc/pmcents/x25AA.gif" border="0" alt="[filled square]" />) in <em>H. pylori</em> strains HP003 (A) and HP032 (B).</span></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head2">Inhibition of urease activity. </span> The comparative inhibitory effects of NE-2001 and acetohydroxamic acid on the urease activities of <em>H. pylori</em> (ATCC43504) and two other sources are shown in Table <a href="articlerender.fcgi?artid=1196265&amp;rendertype=table&amp;id=t2" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">2</a>. Acetohydroxamic acid significantly inhibited urease activities from all three sources when preincubated for 1 h at 37&#x000b0;C, while at a concentration equal to eightfold of the MIC NE-2001 did not show any inhibitory effect on the three ureases in vitro.<div style="margin: 1em; margin-right: 2em;                                 border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="t2" name="t2"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1196265&amp;rendertype=table&amp;id=t2" class="icon-reflink" onclick="startTarget(this, 'table', 1024, 800)"><img src="corehtml/pmc/pmcgifs/table-icon.gif" border="1" class="icon-reflink" alt="TABLE 2." title="TABLE 2."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1196265&amp;rendertype=table&amp;id=t2" onclick="startTarget(this, 'figure', 1024, 800)"><strong>TABLE 2.</strong></a><div class="figure-table-caption-in-article"><span>Inhibitory effects of NE-2001 and acetohydroxamic acid on various ureases</span></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head2">Effect on <em>H. pylori</em> morphology. </span> The morphological alterations of <em>H. pylori</em> cells (ATCC43504) exposed to 2 &#x003bc;g/ml, 4 &#x003bc;g/ml, and 8 &#x003bc;g/ml of NE-2001 for 6 h are shown in Fig. <a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f5" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">5</a>. Transmission electron microscopy demonstrated that NE-2001 treatment induced swelling and vacuole-like structures in the cytoplasm of <em>H. pylori</em> cells. The phenomenon was concentration dependent, and after exposure to 2 (Fig. <a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f5" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">5B</a>) or 4 (Fig. <a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f5" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">5C</a>) &#x003bc;g/ml of NE-2001, the organism changed its appearance from bacilliform to doughnut-shaped form. The bacterium lost its structure and displayed destructive features at 8 &#x003bc;g/ml (Fig. <a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f5" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">5D</a>). Moreover, the outer envelope of an atypically shaped organism was detached from the inner side of the bend.<div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="f5" name="f5"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f5" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=1196265&amp;blobname=zac0080551270005.gif" border="1" class="icon-reflink" alt="FIG. 5." title="FIG. 5."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1196265&amp;rendertype=figure&amp;id=f5" onclick="startTarget(this, 'figure', 1024, 800)"><strong>FIG. 5.</strong></a><div class="figure-table-caption-in-article"><span>Transmission electron micrographs of <em>H. pylori</em> exposed to NE-2001. <em>H. pylori</em> ATCC43504 cells were treated with NE-2001 for 6 h at 0 &#x003bc;g/ml (A), 2 &#x003bc;g/ml (B), 4 &#x003bc;g/ml (C), and 8 &#x003bc;g/ml (D).</span></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head2">Effect on drug-resistant strains of <em>H. pylori</em>. </span> Of the 27 clinical isolates subjected to metronidazole and clarithromycin susceptibility testing, 8 strains were found to be resistant to metronidazole and 5 to be resistant to both metronidazole and clarithromycin. When further exposed to various concentrations of amoxicillin, furazolidone, or NE-2001, the growth of these drug-resistant strains of <em>H. pylori</em> was significantly inhibited, with MICs similar to those reported previously (<a href="#r12" class="cite-reflink bibr">12</a>, <a href="#r20" class="cite-reflink bibr">20</a>) or observed with the standard strain (ATCC43504) (Table <a href="articlerender.fcgi?artid=1196265&amp;rendertype=table&amp;id=t3" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">3</a>). No effect of DMSO or 2-hydroxypropyl-&#x003b2;-cyclodextrin was noted in agar culture plates.<div style="margin: 1em; margin-right: 2em;                                 border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="t3" name="t3"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1196265&amp;rendertype=table&amp;id=t3" class="icon-reflink" onclick="startTarget(this, 'table', 1024, 800)"><img src="corehtml/pmc/pmcgifs/table-icon.gif" border="1" class="icon-reflink" alt="TABLE 3." title="TABLE 3."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1196265&amp;rendertype=table&amp;id=t3" onclick="startTarget(this, 'figure', 1024, 800)"><strong>TABLE 3.</strong></a><div class="figure-table-caption-in-article"><span>Effect of NE-2001 on drug-resistant strains of <em>H. pylori</em></span></div></td></tr></table></div></div><div style="clear:both;"></div></p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: uppercase;">Top</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323173" class="sidefm-pmclink" style="text-transform: uppercase;">Abstract</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323446" class="sidefm-pmclink" style="text-transform: uppercase;">MATERIALS AND METHODS</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323680" class="sidefm-pmclink" style="text-transform: uppercase;">RESULTS</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: uppercase;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>DISCUSSION</a></div><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id324266" class="sidefm-pmclink" style="text-transform: uppercase;">REFERENCES</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: uppercase;" id="id323998">DISCUSSION</div><div class="section-content"><p>Following the recognition of the important pathogenic role of <em>H. pylori</em> infection in the development of gastroduodenal diseases, there has been a continuous search for improved eradication therapy, especially for small molecules with novel mechanism(s) of action. Based on the initial discovery of NE-2001 (<a href="#r4" class="cite-reflink bibr">4</a>), we further tested the antimicrobial activities of this compound against 24 clinical isolates of <em>H. pylori</em>, as presented in this paper. The MIC<sub>90</sub> of NE-2001 was 16 &#x003bc;g/ml, lower than metronidazole and higher than amoxicillin, clarithromycin, and furazolidone. Time-to-kill studies revealed that the anti-<em>H. pylori</em> activity of NE-2001 is of a bactericidal nature, resulting in cell lysis after 6 h of exposure at a concentration of 6.4 &#x003bc;g/ml. In contrast to conventional antibiotics, the effect of NE-2001 is <em>H. pylori</em> specific, with little impact on common aerobic and anaerobic bacteria. This unique selectivity may be attributed to its preferential penetrability to the target site, as has been shown by other hydrophobic compounds of low molecular weight (<a href="#r1" class="cite-reflink bibr">1</a>). The antibiotics currently used in <em>H. pylori</em> eradication all have a broad antibacterial spectrum, and their use would therefore affect the normal gut flora, leading to a series of gastrointestinal side effects. It is expected that NE-2001 may have less liabilities due to its high specificity for <em>H. pylori</em>.</p><p>There have been discrepancies between in vitro bioactivities and clinical efficacies of several antibacterial agents in the clearance of <em>H. pylori</em> from the stomach (<a href="#r22" class="cite-reflink bibr">22</a>). In the Mongolian gerbil model, eradication efficacy was significantly improved by addition of a proton-pump inhibitor (<a href="#r10" class="cite-reflink bibr">10</a>) to clarithromycin or by use of mucoadhesive microspheres containing amoxicillin (<a href="#r15" class="cite-reflink bibr">15</a>). Such augmentation was achieved either through neutralization of the low pH environment or extension of exposure time to the treatment regimen. Obviously, NE-2001 may overcome this deficiency, as it is stable and remains efficacious under acidic conditions.</p><p>The increasing prevalence of <em>H. pylori</em> strains resistant to some of the most commonly used antibacterial agents is the major cause of failure to eradicate the infection (<a href="#r8" class="cite-reflink bibr">8</a>). Some investigators have suggested that secondary resistance to metronidazole and clarithromycin develops very rapidly and thereby limits the usefulness of a number of potentially effective agents (<a href="#r2" class="cite-reflink bibr">2</a>). It was reported previously that the resistance rates of <em>H. pylori</em> to metronidazole and clarithromycin found in randomly collected clinical isolates in Shanghai were 49.7% and 7.3%, respectively (<a href="#r13" class="cite-reflink bibr">13</a>). In addition to confirmation of the above-described observations, we have demonstrated in this study that the clinical strains resistant to metronidazole and clarithromycin were all susceptible to NE-2001 treatment in vitro. It is worth noting that unlike metronidazole, repeated exposure of <em>H. pylori</em> to NE-2001 in vitro did not lead to selection of any resistant mutants. The data, taken together, point to the potential of developing NE-2001 as a novel candidate agent against <em>H. pylori</em> with high sensitivity to certain drug-resistant strains of the bacterium and low frequency of natural resistance.</p><p>It has been shown that urease is an important virulence factor of <em>H. pylori</em> for the development of gastric infection and induction of damages to the gastric mucosa (<a href="#r5" class="cite-reflink bibr">5</a>). However, NE-2001 did not display any inhibitory effect on <em>H. pylori</em> urease activity compared to acetohydroxamic acid, a widely used urease inhibitor. This result indicates that the inhibitory action of NE-2001 on the growth of <em>H. pylori</em> is independent of urease. Our previous study demonstrated that the effect of NE-2001 is mediated through an inhibition of the bacterial DNA replication mechanism (<a href="#r4" class="cite-reflink bibr">4</a>), but the exact molecular target for NE-2001 remains to be investigated.</p><p>The marked morphological changes of <em>H. pylori</em> cells following exposure to NE-2001 include swelling of the bacilliforms, development of numerous blebs on cell surface, and emergence of vacuole-like structures in the cytoplasm. These observations suggest that the target whereby NE-2001 exerts its biological effect may be located on the cell surface that functions as a permeability barrier. Conceivably, the bactericidal mechanism of NE-2001 against <em>H. pylori</em> may be the result of its perturbation of the permeability barrier within cell membranes. Nevertheless, other mechanisms of action could not be ruled out, including interruption of <em>H. pylori</em> colonization (<a href="#r17" class="cite-reflink bibr">17</a>).</p><p>In conclusion, the new chemical entity, NE-2001, is highly selective in inhibiting the growth of <em>H. pylori</em> with moderate concentrations at neutral pH and under acidic conditions. This in vitro effect of NE-2001 may have the potential when given orally to decrease the viability of <em>H. pylori</em> in the stomach or gastric mucus, thereby relieving pathological damages caused by the bacterium. Further studies will be directed towards the exploration of NE-2001 to become a new and locally acting therapeutic agent to treat <em>H. pylori</em> infection.</p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"> </td><td class="content-cell"><div class="head1 section-title" style="text-transform: uppercase;" id="id324255">Acknowledgments</div><div class="section-content"><p><p>This work was supported by the National Natural Science Foundation of China Grant (30271555 to D.X.Z.) and grants from the Shanghai Municipality Science &#x00026; Technology Development Fund (014319238 and 044319220 to M.W.W.), the Ministry of Science and Technology of China (2002AA2Z343A to M.W.W.), and the Chinese Academy of Sciences (KSCX1-SW-11-2 to M.W.W.).</p><p>We are indebted to Weiwen Xu for technical assistance, Qing Zheng for patient specimen and data collection, and Dale E. Mais for valuable comments and critical review of the manuscript.</p></p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: uppercase;">Top</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323173" class="sidefm-pmclink" style="text-transform: uppercase;">Abstract</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323446" class="sidefm-pmclink" style="text-transform: uppercase;">MATERIALS AND METHODS</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323680" class="sidefm-pmclink" style="text-transform: uppercase;">RESULTS</a></div></span><span style="text-transform: uppercase;"><div class="sidefm-pmclink-item"><a href="#id323998" class="sidefm-pmclink" style="text-transform: uppercase;">DISCUSSION</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: uppercase;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>REFERENCES</a></div></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: uppercase;" id="id324266">REFERENCES</div><div class="section-content"><div class="back-matter-section"><div class="ref-cit-blk" id="r1"><div class="ref-label">1.</div><div class="ref-cit"><strong>Bina, J. E., R. A. Alm, M. Uria-Nickelsen, S. R. Thomas, T. J. Trust, and R. E. W. Hancock.</strong> 2000. <em>Helicobacter pylori</em> uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. <span class="ref-journal">Antimicrob. Agents Chemother.</span> <span class="ref-vol">44</span><strong>:</strong>248-254.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0x30O4I7OCTZgq7oFszJm_K5NE7JM5fiNiFaG-ksy&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/10639345">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r2"><div class="ref-label">2.</div><div class="ref-cit"><strong>Bj&#x000f6;rkholm, B., M. Sj&#x000f6;lund, P. G. Falk, O. G. Berg, L. Engstrand, and D. I. Andersson.</strong> 2001. Mutation frequency and biological cost of antibiotic resistance in <em>Helicobacter pylori</em>. <span class="ref-journal">Proc. Natl. Acad. Sci. USA</span> <span class="ref-vol">98</span><strong>:</strong>14607-14612.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0BclTm1sIBspOMQhLx_qVF90SEj85qpOkcKpebQd6&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/11717398">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r3"><div class="ref-label">3.</div><div class="ref-cit"><strong>Blaser, M.</strong> 1997. Ecology of <em>Helicobacter pylori</em> in the human stomach. <span class="ref-journal">J. Clin. Investig.</span> <span class="ref-vol">100</span><strong>:</strong>759-762.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0HEET_48qsGwIXRHR6YGyZPdI04XFGIBnfNMfXAWh&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9259572">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r4"><div class="ref-label">4.</div><div class="ref-cit"><strong>Cheng, N., J. S. Xie, M. Y. Zhang, C. Shu, and D. X. Zhu.</strong> 2003. A specific anti-<em>Helicobacter pylori</em> agent NE2001: synthesis and its effect on the growth of <em>H. pylori</em>. <span class="ref-journal">Bioorg. Med. Chem. Lett.</span> <span class="ref-vol">13</span><strong>:</strong>2703-2707.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0rW9w8utLyfbEYN3MWoNiWOLuM8KJpFgmzFGwRkxP&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/12873498">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r5"><div class="ref-label">5.</div><div class="ref-cit"><strong>Dunn, B. E., H. Cohen, and M. J. Blaser.</strong> 1997. <em>Helicobacter pylori</em>. <span class="ref-journal">Clin. Microbiol. Rev.</span> <span class="ref-vol">10</span><strong>:</strong>720-741.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0BkYlBGudekCqjBPgMohvGBOqihRbdJxUhML1Wk2_&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9336670">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r6"><div class="ref-label">6.</div><div class="ref-cit"><strong>Forman, D., D. G. Newell, F. Fullerton, J. W. Yarnell, A. R. Stacey, N. Wald, and F. Sitas.</strong> 1991. Association between infection with <em>Helicobacter pylori</em> and risk of gastric cancer: evidence from a prospective investigation. <span class="ref-journal">Br. Med. J.</span> <span class="ref-vol">302</span><strong>:</strong>302-305.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0FSKgpNu8PXMPE20NnCsY75uZTO1-QlbwcfRxrAVY&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/2001503">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r7"><div class="ref-label">7.</div><div class="ref-cit"><strong>Genta, R. M., I. E. Gurer, and D. Y. Graham.</strong> 1995. Geographical pathology of <em>Helicobacter pylori</em> infection: is there more than one gastritis? <span class="ref-journal">Ann. Med.</span> <span class="ref-vol">27</span><strong>:</strong>595-599.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0zcT_uxhz8R1b_OoV-S40k8-mYgaHHIwH7dL84kfK&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8541038">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r8"><div class="ref-label">8.</div><div class="ref-cit"><strong>Gisbert, J. P., and J. M. Pajares.</strong> 2001. <em>Helicobacter pylori</em> therapy: first-line options and rescue regimen. <span class="ref-journal">Dig. Dis.</span> <span class="ref-vol">19</span><strong>:</strong>134-143.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0J78Av2BcNOmbqL5b35Cay7AX5GO8e-MlVKeUKkDt&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/11549823">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r9"><div class="ref-label">9.</div><div class="ref-cit"><strong>Jenks, P. J., and D. I. Edwards.</strong> 2002. Metronidazole resistance in <em>Helicobacter pylori</em>. <span class="ref-journal">Int. J. Antimicrob. Agents</span> <span class="ref-vol">19</span><strong>:</strong>1-7.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0R18ifRXfcvsmXOaY743AzAcMudue33_lndQt6k7-&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/11814762">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r10"><div class="ref-label">10.</div><div class="ref-cit"><strong>Keto, Y., S. Takahashi, and S. Okabe.</strong> 1999. Healing of <em>Helicobacter pylori</em>-induced gastric ulcers in Mongolian gerbils: combined treatment with omeprazole and clarithromycin. <span class="ref-journal">Dig. Dis. Sci.</span> <span class="ref-vol">44</span><strong>:</strong>257-265.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0nyZg8FW46q5eNT_zNr2UvlNBVx0qRYFV4hGrx55B&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/10063909">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r11"><div class="ref-label">11.</div><div class="ref-cit"><strong>Kwon, D. H., J. J. Kim, M. Lee, Y. Yamaoka, M. Kato, M. S. Osato, F. A. El-Zaatari, and D. Y. Graham.</strong> 2000. Isolation and characterization of tetracycline-resistant clinical isolates of <em>Helicobacter pylori</em>. <span class="ref-journal">Antimicrob. Agents Chemother.</span> <span class="ref-vol">44</span><strong>:</strong>3203-3205.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0XC9DiuWDsVXMRx-ymyGj5_G_I5R7Hn4FmJ9F65lH&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/11036054">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r12"><div class="ref-label">12.</div><div class="ref-cit"><strong>Kwon, D. H., M. Lee, J. J. Kim, J. G. Kim, F. A. K. El-Zaatari, M. S. Osato, and D. Y. Graham.</strong> 2001. Furazolidone- and nitrofurantoin-resistant <em>Helicobacter pylori</em>: prevalence and role of genes involved in metronidazole resistance. <span class="ref-journal">Antimicrob. Agents Chemother.</span> <span class="ref-vol">45</span><strong>:</strong>306-308.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0xMkJ_PDb5PmdgJUMk9GBXvq_WB-SWPBh9Orhb5ko&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/11120984">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r13"><div class="ref-label">13.</div><div class="ref-cit"><strong>Liang, X., W. Z. Liu, H. Lu, W. W. Xu, and S. D. Xiao.</strong> 2003. <em>Helicobacter pylori</em>: in vitro induction of resistance to antibiotics and surveillances of its resistance prevalence. <span class="ref-journal">Chin. J. Dig.</span> <span class="ref-vol">23</span><strong>:</strong>146-149.</div></div><div class="ref-cit-blk" id="r14"><div class="ref-label">14.</div><div class="ref-cit"><strong>Malfertheiner, P., F. Megraud, C. O'Morain, A. P. Hungin, R. Jones, A. Axon, D. Y. Graham, G. Tytgat, and European</strong> <em>Helicobacter Pylori</em> Study Group (EHPSG). 2002. Current concepts in the management of <em>Helicobacter pylori</em> infection&#x02014;the Maastricht 2-2000 Consensus Report. <span class="ref-journal">Aliment. Pharmacol. Ther.</span> <span class="ref-vol">16</span><strong>:</strong>167-180.</div></div><div class="ref-cit-blk" id="r15"><div class="ref-label">15.</div><div class="ref-cit"><strong>Nagahara, N., Y. Akiyama, M. Nakao, M. Tada, M. Kitano, and Y. Ogawa.</strong> 1998. Mucoadhesive microspheres containing amoxicillin for clearance of <em>Helicobacter pylori</em>. <span class="ref-journal">Antimicrob. Agents Chemother.</span> <span class="ref-vol">42</span><strong>:</strong>2492-2494.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0z_MeoiOSin7FcddhvtvyVk93IAG8Ic7SoOF_IQm5&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9756746">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r16"><div class="ref-label">16.</div><div class="ref-cit"><strong>National Committee for Clinical Laboratory Standards.</strong> 2003. Performance standards for antimicrobial susceptibility testing and approved standard M7-A6. Informational supplement M100-S15 (2005). National Committee for Clinical Laboratory Standards, Wayne, PA.</div></div><div class="ref-cit-blk" id="r17"><div class="ref-label">17.</div><div class="ref-cit"><strong>O'Rourke, E. J., C. Chevalier, A. V. Pinto, J. M. Thiberge, L. Ielpi, A. Labigne, and J. P. Radicella.</strong> 2003. Pathogen DNA as target for host-generated oxidative stress: role for repair of bacterial DNA damage in <em>Helicobacter pylori</em> colonization. <span class="ref-journal">Proc. Natl. Acad. Sci. USA</span> <span class="ref-vol">100</span><strong>:</strong>2789-2794.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=02193EReY4o22XaGnr_7r6kC47YnvsZ5iNHZkwkNe&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/12601164">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r18"><div class="ref-label">18.</div><div class="ref-cit"><strong>Osato, M. S., R. Reddy, S. G. Reddy, R. L. Penland, H. M. Malaty, and D. Y. Graham.</strong> 2001. Pattern of primary resistance of <em>Helicobacter pylori</em> to metronidazole or clarithromycin in the United States. <span class="ref-journal">Arch. Intern. Med.</span> <span class="ref-vol">161</span><strong>:</strong>1217-1220.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0JwDLdNinPv29yz-do9SVc76lRaaT25yXGP-8mAjK&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/11343444">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r19"><div class="ref-label">19.</div><div class="ref-cit"><strong>Penner, J. L.</strong> 1991. <em>Campylobacter</em>, <em>Helicobacter</em>, and related spiral bacteria, p. 402-409. <em>In</em> A. Aslows, W. J. Hausler, K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), <span class="ref-journal">Manual of clinical microbiology</span>, 5th ed. American Society for Microbiology, Washington, D.C.</div></div><div class="ref-cit-blk" id="r20"><div class="ref-label">20.</div><div class="ref-cit"><strong>Piccolomini, R., G. D. Bonaventura, G. Catamo, F. Carbone, and M. Neri.</strong> 1997. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of <em>Helicobacter pylori</em> strains to 20 antimicrobial agents. <span class="ref-journal">J. Clin. Microbiol.</span> <span class="ref-vol">35</span><strong>:</strong>1842-1846.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0BQn0N30LHRLhiOFqzBsHoG1dFtiNHYz8Al3gi5F9&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9196205">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r21"><div class="ref-label">21.</div><div class="ref-cit"><strong>Pina, M., A. Occhialini, L. Monteiro, H.-P. Doermann, and F. M&#x000e9;graud.</strong> 1998. Detection of point mutations associated with resistance of <em>Helicobacter pylori</em> to clarithromycin by hybridization in liquid phase. <span class="ref-journal">J. Clin. Microbiol.</span> <span class="ref-vol">36</span><strong>:</strong>3285-3290.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=02agElJu1i2CxCHt4qiYcs5XjL1aiqoxghH9xnAow&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9774580">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r22"><div class="ref-label">22.</div><div class="ref-cit"><strong>Stone, J. W., R. Wise, I. A. Donovan, and J. Gearty.</strong> 1988. Failure of ciprofloxacin to eradicate <em>Campylobacter pylori</em> from the stomach. <span class="ref-journal">J. Antimicrob. Chemother.</span> <span class="ref-vol">22</span><strong>:</strong>92-93.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0hwB-h8VBI8_JRo1P9TE7BOk8d9fil3Lvah2KAQYl&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/3170399">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r23"><div class="ref-label">23.</div><div class="ref-cit"><strong>Wu, H., X. D. Shi, H. T. Wang, and J. X. Liu.</strong> 2000. Resistance of <em>Helicobacter pylori</em> to metronidazole, tetracycline and amoxycillin. <span class="ref-journal">J. Antimicrob. Chemother.</span> <span class="ref-vol">46</span><strong>:</strong>121-123.  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0HUv94mk4P_VDECIFCaAWTL6KKtnL2bTef2srfkkv&amp;reftype=pubmed&amp;artid=1196265&amp;article-id=1196265&amp;iid=120965&amp;issue-id=120965&amp;jid=82&amp;journal-id=82&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/10882700">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="r24"><div class="ref-label">24.</div><div class="ref-cit"><strong>Zhu, D. X., M. Muramatsu, J. S. Xie, N. Cheng, and M.-W. Wang.</strong> May;2004. Methods and compositions for treating or preventing bacterial infection. U.S. patent 6734212B2.</div></div></div></div></td></tr><tr><td></td><td class="content-cell"><div class="footer-section"><hr><div class="sans90" style="margin: 0em 1em 1em; text-align: center;">Articles from <span class="acknowledgment-journal-title">Antimicrobial Agents and Chemotherapy</span> are provided here courtesy of <br><b>American Society for Microbiology (ASM)</b></div>
      <div class="footer-link" id="fp-footer">
        <div>
          <a class="link" href="mailto:pubmedcentral@nih.gov">Write to PMC</a>
           | 
          <a class="link" href="./">PMC Home</a>
           | 
          <a class="link" href="http://www.ncbi.nlm.nih.gov/pubmed">PubMed</a>
        </div>
        <div>
          <a class="link" href="http://www.ncbi.nlm.nih.gov">NCBI</a>
           | 
          <a class="link" href="http://www.nlm.nih.gov">U.S. National Library of Medicine</a>
        </div>
        <div>
          <a class="link" href="http://www.nih.gov">NIH</a>
           | 
          <a class="link" href="http://www.hhs.gov/">Department of Health and Human Services</a>
        </div>
        <div>
          <a class="link" href="about/privacypolicy.html">Privacy Policy</a>
           | 
          <a class="link" href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Disclaimer</a>
           | 
          <a class="link" href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act</a>
        </div>
      </div>
    </div></td></tr></table></body></html><!--host:ipmc2-->

